Titre : Biodisponibilité

Biodisponibilité : Questions médicales fréquentes

Termes MeSH sélectionnés :

Learning Disabilities
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Biodisponibilité : Questions médicales les plus fréquentes", "headline": "Biodisponibilité : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Biodisponibilité : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-31", "dateModified": "2025-04-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Biodisponibilité" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pharmacocinétique", "url": "https://questionsmedicales.fr/mesh/D010599", "about": { "@type": "MedicalCondition", "name": "Pharmacocinétique", "code": { "@type": "MedicalCode", "code": "D010599", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G07.690.725" } } }, "about": { "@type": "MedicalCondition", "name": "Biodisponibilité", "alternateName": "Biological Availability", "code": { "@type": "MedicalCode", "code": "D001682", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "William Green", "url": "https://questionsmedicales.fr/author/William%20Green", "affiliation": { "@type": "Organization", "name": "York Health Economics Consortium, York, UK." } }, { "@type": "Person", "name": "Richard Stork", "url": "https://questionsmedicales.fr/author/Richard%20Stork", "affiliation": { "@type": "Organization", "name": "Almirall, Uxbridge, UK." } }, { "@type": "Person", "name": "Aina Pi Blanque", "url": "https://questionsmedicales.fr/author/Aina%20Pi%20Blanque", "affiliation": { "@type": "Organization", "name": "Almirall S.A, Barcelona, Spain." } }, { "@type": "Person", "name": "Ayeda Nadeem", "url": "https://questionsmedicales.fr/author/Ayeda%20Nadeem", "affiliation": { "@type": "Organization", "name": "York Health Economics Consortium, York, UK." } }, { "@type": "Person", "name": "Morgane C Mouslim", "url": "https://questionsmedicales.fr/author/Morgane%20C%20Mouslim", "affiliation": { "@type": "Organization", "name": "The Center for Drug Safety and Effectiveness and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The online mindset intervention 'The Growth Factory' for adolescents with intellectual disabilities: moderators and mediators.", "datePublished": "2022-09-01", "url": "https://questionsmedicales.fr/article/36047578", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jir.12970" } }, { "@type": "ScholarlyArticle", "name": "The adaptive ability performance test (ADAPT): A factor analytic study in clients with intellectual disabilities.", "datePublished": "2022-10-26", "url": "https://questionsmedicales.fr/article/36288909", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jar.13044" } }, { "@type": "ScholarlyArticle", "name": "Eye-tracking training improves the learning and memory of children with learning difficulty.", "datePublished": "2022-08-17", "url": "https://questionsmedicales.fr/article/35977994", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-18286-6" } }, { "@type": "ScholarlyArticle", "name": "Aggressive behaviour of psychiatric patients with mild and borderline intellectual disabilities in general mental health care.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36190995", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0272502" } }, { "@type": "ScholarlyArticle", "name": "Prevalence and trends of developmental disabilities among US children and adolescents aged 3 to 17 years, 2018-2021.", "datePublished": "2023-10-12", "url": "https://questionsmedicales.fr/article/37828147", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-44472-1" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques", "item": "https://questionsmedicales.fr/mesh/D010829" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes pharmacologiques et toxicologiques", "item": "https://questionsmedicales.fr/mesh/D002620" }, { "@type": "ListItem", "position": 4, "name": "Pharmacocinétique", "item": "https://questionsmedicales.fr/mesh/D010599" }, { "@type": "ListItem", "position": 5, "name": "Biodisponibilité", "item": "https://questionsmedicales.fr/mesh/D001682" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Biodisponibilité - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Biodisponibilité", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Biodisponibilité", "description": "Comment évaluer la biodisponibilité d'un médicament ?\nQuels tests sont utilisés pour mesurer la biodisponibilité ?\nLa biodisponibilité est-elle la même pour tous les médicaments ?\nQuels facteurs influencent la biodisponibilité ?\nComment la biodisponibilité est-elle mesurée ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Biodisponibilité", "description": "Quels symptômes indiquent une faible biodisponibilité ?\nPeut-on ressentir des effets secondaires d'une biodisponibilité élevée ?\nComment la biodisponibilité affecte-t-elle les symptômes ?\nLes symptômes varient-ils selon la voie d'administration ?\nQuels symptômes peuvent indiquer une surdose liée à la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Biodisponibilité", "description": "Comment prévenir une biodisponibilité faible ?\nL'alimentation influence-t-elle la biodisponibilité ?\nQuelles habitudes de vie favorisent une bonne biodisponibilité ?\nLes médicaments doivent-ils être pris à jeun ?\nComment éviter les interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Biodisponibilité", "description": "Comment améliorer la biodisponibilité d'un médicament ?\nQuels traitements augmentent la biodisponibilité ?\nLes médicaments à libération prolongée affectent-ils la biodisponibilité ?\nComment la biodisponibilité influence-t-elle le choix du traitement ?\nLes suppléments nutritionnels affectent-ils la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Biodisponibilité", "description": "Quelles complications peuvent résulter d'une biodisponibilité élevée ?\nUne biodisponibilité faible peut-elle causer des complications ?\nComment les complications sont-elles liées à la biodisponibilité ?\nLes complications peuvent-elles être évitées par une bonne biodisponibilité ?\nQuels sont les risques de surdosage liés à la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Biodisponibilité", "description": "Quels facteurs augmentent le risque d'une biodisponibilité faible ?\nLe tabagisme affecte-t-il la biodisponibilité ?\nLes maladies chroniques influencent-elles la biodisponibilité ?\nL'âge influence-t-il la biodisponibilité ?\nLes habitudes alimentaires affectent-elles la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer la biodisponibilité d'un médicament ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des études pharmacocinétiques pour mesurer la concentration dans le sang." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer la biodisponibilité ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des études de bioéquivalence sont couramment utilisés." } }, { "@type": "Question", "name": "La biodisponibilité est-elle la même pour tous les médicaments ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle varie selon la voie d'administration et la formulation du médicament." } }, { "@type": "Question", "name": "Quels facteurs influencent la biodisponibilité ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'alimentation, le pH gastrique et la présence d'autres médicaments peuvent l'affecter." } }, { "@type": "Question", "name": "Comment la biodisponibilité est-elle mesurée ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle est mesurée par le rapport entre la concentration plasmatique et la dose administrée." } }, { "@type": "Question", "name": "Quels symptômes indiquent une faible biodisponibilité ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes d'inefficacité du traitement, comme la persistance de la maladie." } }, { "@type": "Question", "name": "Peut-on ressentir des effets secondaires d'une biodisponibilité élevée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une biodisponibilité élevée peut entraîner des effets secondaires plus marqués." } }, { "@type": "Question", "name": "Comment la biodisponibilité affecte-t-elle les symptômes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une biodisponibilité insuffisante peut retarder la réponse thérapeutique et aggraver les symptômes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon la voie d'administration ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon que le médicament est pris par voie orale ou intraveineuse." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une surdose liée à la biodisponibilité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes tels que nausées, vertiges ou confusion peuvent indiquer une surdose." } }, { "@type": "Question", "name": "Comment prévenir une biodisponibilité faible ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "En respectant les recommandations d'administration et en évitant les interactions médicamenteuses." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la biodisponibilité ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains aliments peuvent augmenter ou diminuer la biodisponibilité des médicaments." } }, { "@type": "Question", "name": "Quelles habitudes de vie favorisent une bonne biodisponibilité ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une hydratation adéquate et une alimentation équilibrée peuvent favoriser une bonne biodisponibilité." } }, { "@type": "Question", "name": "Les médicaments doivent-ils être pris à jeun ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend du médicament; certains nécessitent d'être pris à jeun pour une meilleure biodisponibilité." } }, { "@type": "Question", "name": "Comment éviter les interactions médicamenteuses ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "En consultant un professionnel de santé avant de prendre plusieurs médicaments simultanément." } }, { "@type": "Question", "name": "Comment améliorer la biodisponibilité d'un médicament ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "On peut utiliser des formulations spécifiques ou des co-administrations pour l'optimiser." } }, { "@type": "Question", "name": "Quels traitements augmentent la biodisponibilité ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sous forme injectable ont généralement une biodisponibilité plus élevée." } }, { "@type": "Question", "name": "Les médicaments à libération prolongée affectent-ils la biodisponibilité ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent améliorer la biodisponibilité en libérant le principe actif sur une période prolongée." } }, { "@type": "Question", "name": "Comment la biodisponibilité influence-t-elle le choix du traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elle guide le choix de la voie d'administration et la posologie pour maximiser l'efficacité." } }, { "@type": "Question", "name": "Les suppléments nutritionnels affectent-ils la biodisponibilité ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains suppléments peuvent interagir et modifier la biodisponibilité des médicaments." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter d'une biodisponibilité élevée ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Une biodisponibilité élevée peut entraîner des effets indésirables graves ou une toxicité." } }, { "@type": "Question", "name": "Une biodisponibilité faible peut-elle causer des complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner un échec thérapeutique et des complications liées à la maladie." } }, { "@type": "Question", "name": "Comment les complications sont-elles liées à la biodisponibilité ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications surviennent souvent lorsque la concentration du médicament est insuffisante ou excessive." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées par une bonne biodisponibilité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une biodisponibilité adéquate peut réduire le risque de complications liées au traitement." } }, { "@type": "Question", "name": "Quels sont les risques de surdosage liés à la biodisponibilité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un surdosage peut survenir si la biodisponibilité est trop élevée, entraînant des effets toxiques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'une biodisponibilité faible ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, les maladies gastro-intestinales et les interactions médicamenteuses peuvent l'augmenter." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il la biodisponibilité ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut modifier le métabolisme des médicaments, affectant leur biodisponibilité." } }, { "@type": "Question", "name": "Les maladies chroniques influencent-elles la biodisponibilité ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme le diabète ou l'insuffisance hépatique peuvent altérer la biodisponibilité." } }, { "@type": "Question", "name": "L'âge influence-t-il la biodisponibilité ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir une biodisponibilité modifiée en raison de changements physiologiques." } }, { "@type": "Question", "name": "Les habitudes alimentaires affectent-elles la biodisponibilité ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en graisses ou en fibres peut influencer la biodisponibilité des médicaments." } } ] } ] }

Sources (10000 au total)

The online mindset intervention 'The Growth Factory' for adolescents with intellectual disabilities: moderators and mediators.

The online mindset intervention The Growth Factory (TGF) has shown promising effects-increasing growth mindsets and perseverance and decreasing mental health problems among youth with intellectual dis... The sample consisted of 119 participants with mild to borderline ID (M... Findings indicated that the effectiveness of TGF was not affected by participants' baseline mindsets, age and ID level. TGF was more effective in reducing internalising problems in girls and increasin... TGF offers a universal, 'add-on' mindset intervention complementing usual care programmes. It improves mindsets, perseverance and mental health in youth with ID. Both practical and theoretical implica...

The adaptive ability performance test (ADAPT): A factor analytic study in clients with intellectual disabilities.

The adaptive ability performance test (ADAPT) was developed to assess adaptive skills in individuals with intellectual disabilities and borderline intellectual functioning, with or without mental diso... One thousand and sixty six ADAPTs from clients with (suspected) intellectual disabilities or borderline intellectual functioning and 129 ADAPTs from participants from the general population were colle... An exploratory factor analysis (EFA) was performed and resulted in good fit indices. Subsequent confirmatory factor analysis (CFA) and multigroup CFA showed acceptable to good fit indices. This result... Factor analytic results suggest that the ADAPT is a valid instrument that measures adaptive skills in individuals with intellectual disabilities or borderline intellectual functioning....

Aggressive behaviour of psychiatric patients with mild and borderline intellectual disabilities in general mental health care.

Little is known about the associations between mild intellectual disability (MID), borderline intellectual functioning (BIF) and aggressive behaviour in general mental health care. The study aims to e... 1174 out of 1565 consecutive in-and outpatients were screened for MID/BIF with the Screener for Intelligence and Learning Disabilities (SCIL) in general mental health care in The Netherlands. During t... Forty-one percent of participating patients were screened positive for MID/BIF. Patients with assumed MID/BIF showed significantly more aggression at the patient and sample level (odds ratio (OR) of 2... We found an increased risk for aggression and physical aggression in patients with assumed MID/BIF. We recommend screening for intellectual functioning at the start of treatment and using measures to ...

Psychometric properties of measures designed to assess common mental health problems and wellbeing in adults with intellectual disabilities: a systematic review.

Multiple measures of mental health problems and mental wellbeing for adults with intellectual disabilities are available, but investigations into their reliability and validity are still in the early ... A systematic search was performed across three databases (MEDLINE, PsycINFO and SCOPUS). The literature search was limited to the years from 2009 to 2021 and to the original English versions. Ten pape... Four measures had at least one rating of 'good' across both dimensions of reliability and at least one dimension of validity and were deemed to have promising psychometric properties: the Clinical Out... This review informs measurement choice for researchers and clinicians while highlighting a need for continued research efforts into the quality of measures available for people with IDs. The results w...

Working memory training in children with neurodevelopmental disorders and intellectual disabilities, the role of coaching: A double-blind randomised controlled trial.

Working memory training (WMT) can offer therapeutic benefits to patients with neurodevelopmental disorders (NDD) and mild to borderline intellectual disability (MBID). However, consistent evidence for... A double-blind randomised controlled trial in children (aged 10;0-13;11) with MBID (60 < IQ < 85) and ADHD and/or ASD evaluated the effects of a less intensive but prolonged version of the original Co... We observed a significant effect of time on both primary and secondary outcome measures, indicating that all children improved in working memory performance and other neurocognitive and academic outco... This study was unable to document superior effects of active personalised coaching and feedback compared with general non-personalised coaching and no feedback in an adaptive WMT in children with MBID...

The predictive value of the dynamic risk outcome scales (DROS) for recidivism in (forensic) clients with mild intellectual disabilities or borderline intellectual functioning.

The dynamic risk outcome scales (DROS) was developed to assess treatment progress of clients with mild intellectual disability or borderline intellectual functioning using dynamic risk factors. We stu... Data of 250 forensic clients with intellectual disabilities were linked to recidivism data from the Judicial Information Service in the Netherlands. Receiver operating characteristics (ROC) analyses w... The DROS total score could not significantly predict recidivism. A DROS recidivism subscale predicted general, violent and other recidivism. These predictive values were comparable to those of a Dutch... The DROS recidivism subscale predicted various classifications of recidivism better than chance. At present, the DROS appears to have no added value beyond the HKT-30 for the purpose of risk assessmen...

The relationship between bullying, learning disorders and psychiatric comorbidity.

Both learning disorders and bullying are major sources of public concern. Children with learning disorders often suffer from social rejection, potentially rendering them more susceptible to bullying i... The current study used path analyses on a representative sample of 2,925 German 3rd and 4th grades to examine whether learning disorders are a direct bullying risk factor, or whether their impact depe... Results indicated that learning disorders are not a direct but rather an indirect childhood risk factor for bully-victim involvement, depending on psychiatric comorbidity with internalizing or externa... Children with learning disorders are at a higher risk of having psychiatric comorbidity, which in turn renders them at a higher risk of bullying involvement. Implications for bullying interventions an...